Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

被引：0
|
作者：
Kristian Reich
April W. Armstrong
Peter Foley
Michael Song
Megan Miller
Y. K. Shen
Yin You
Chenglong Han
Kenneth B. Gordon
机构：
[1] University Medical Center Hamburg-Eppendorf,Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing
[2] University of Southern California,Department of Dermatology, Keck School of Medicine
[3] The University of Melbourne,Department of Medicine
[4] St. Vincent’s Hospital Melbourne and Probity Medical Research,undefined
[5] Skin Health Institute,undefined
[6] Janssen Research & Development,undefined
[7] LLC,undefined
[8] Janssen Global Services,undefined
[9] LLC,undefined
[10] Medical College of Wisconsin,undefined
来源：
American Journal of Clinical Dermatology | 2020年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：881 / 890
页数：9
相关论文
共 50 条
  • [41] Malignancy rates and comparisons to the general US population through 3 years in guselkumab-treated moderate-to-severe psoriasis patients in VOYAGE 1&2
    Papp, K. A.
    Reich, K.
    Gordon, K. B.
    Lebwohl, M.
    Song, M.
    Ramachandran, P.
    Randazzo, B.
    Shen, Y. -K.
    Blauvelt, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 102 - 102
  • [42] Efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis with involvement of the scalp, nails, hands, and feet: Results from the phase 3 VOYAGE 2 study
    Reich, Kristian
    Armstrong, April W.
    Foley, Peter
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    Shen, Yaung-Kaung
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [43] EFFICACY RESPONSES ACROSS DISEASE SEVERITY AND TREATMENT HISTORY SUBGROUPS OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TREATED WITH GUSELKUMAB: POOLED RESULTS FROM VOYAGE-1 AND VOYAGE-2 THROUGH 5 YEARS
    Gordon, K.
    Merola, J. F.
    Foley, P.
    Choi, O.
    Chan, D.
    Miller, M.
    You, Y.
    Shen, Y. K.
    Yang, Y. W.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1842 - 1842
  • [44] Malignancy rates through 5 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis: Results from the VOYAGE 1 and 2 trials and comparisons to general populations
    Blauvelt, Andrew
    Langley, Richard G.
    Ho, Vincent
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB79 - AB79
  • [45] Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study
    Gordon, K. B.
    Armstrong, A. W.
    Han, C.
    Foley, P.
    Song, M.
    Wasfi, Y.
    You, Y.
    Shen, Y. -K.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (11) : 1940 - 1949
  • [46] Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2
    Reich, K.
    Gordon, K. B.
    Strober, B. E.
    Armstrong, A. W.
    Miller, M.
    Shen, Y. K.
    You, Y.
    Han, C.
    Yang, Y. W.
    Foley, P.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1146 - 1159
  • [47] Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis
    Lebwohl, M.
    Langley, R. G.
    Zhu, Y.
    Zhou, H.
    Song, M.
    Shen, Y. K.
    Lafferty, K. Parnell
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (11) : 2082 - 2086
  • [48] Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 VOYAGE 1 study
    Blauvelt, Andrew
    Papp, Kim
    Griffiths, Christopher E. M.
    Randazzo, Bruce
    Wasfi, Yasmine
    Shen, Yaung-Kaung
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [49] Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Peterson, Steven
    Yang, Feifei
    Adejoro, Oluwakayode
    Kollmeier, Alexa P.
    Shiff, Natalie J.
    Han, Chenglong
    Shawi, May
    Tillett, William
    Mease, Philip J.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (02) : 425 - 441
  • [50] Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
    Jeffrey R. Curtis
    Iain B. McInnes
    Proton Rahman
    Dafna D. Gladman
    Steven Peterson
    Feifei Yang
    Oluwakayode Adejoro
    Alexa P. Kollmeier
    Natalie J. Shiff
    Chenglong Han
    May Shawi
    William Tillett
    Philip J. Mease
    Rheumatology and Therapy, 2024, 11 : 425 - 441
12345